Patient screening is underway in a U.S.-based clinical trial of NKX019, an investigational natural killer (NK) cell therapy for people with treatment-resistant lupus nephritis, a serious complication of lupus, its developer, Nkarta, announced. The trial, called Ntrust-1, is a multicenter and open-label study to assess the safety,…
A number of former NFL players joined 2009 Super Bowl champ Willie Colon this past week for the 10th anniversary of a golf event that is anticipated to raise $450,000 this year for the Lupus Research Alliance (LRA) to support the fight against lupus. The annual Willie Colon…
Nearly all people with systemic lupus erythematosus (SLE) treated with iCell Gene Therapeutics’ dual-target CAR T-cell therapy achieved medication-free disease remission, according to long-term follow-up data from a small Phase 1 trial. Further, kidney function continued to improve among those with lupus nephritis (LN), a common SLE complication…
Mutations in the UNC93B1 gene — which produces a protein involved in the regulation of certain immune proteins, called toll-like receptors, or TLRs — may drive autoimmunity in people with lupus and other autoimmune conditions, according to a new study into the genetic cause of lupus and related diseases.
Discontinuing glucocorticoid therapy after achieving remission did not increase the risk of symptom flare-ups in people with systemic lupus erythematosus (SLE). That’s according to data presented at the 2024 European Alliance of Associations for Rheumatology (EULAR) congress, as announced in a EULAR press release. Data also showed that…
The six recipients of Lupus Foundation of America (LFA)’s 2024 fellowships for young scientists will use their awards to study several areas of lupus, ranging from lupus nephritis to the connection between physical activity and physical function in people with the autoimmune disease. The goal of the 40-year-old…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to CAR T-cell therapy ADI-001 as a potential treatment for lupus nephritis, a lupus complication marked by kidney damage and inflammation. The FDA gives fast track status to experimental treatments that have the potential to fill unmet…
GRI Bio announced what it called “encouraging preclinical data” on two systemic lupus erythematosus (SLE) treatment candidates. SLE is the most common form of lupus. GRI-0124, an oral small molecule being developed to activate natural killer T-cells, or NKT cells, and keep autoimmune attacks in check eased inflammation…
A dual-target CAR T-cell therapy from iCell Gene Therapeutics safely led to medication-free disease remission for systemic lupus erythematosus (SLE) patients in a small Phase 1 study. For patients with lupus nephritis (LN), a common and serious SLE manifestation involving the kidneys, renal function also was improved. Based…
The U.S. Food and Drug Administration (FDA) has approved the use of Benlysta (belimumab) in a prefilled autoinjector as an add-on treatment for children ages 5 and older with systemic lupus erythematosus (SLE), the most common form of lupus. This is the first time children with active disease…